Log in

S2B Syn2bio Spolka Akcyjna GPW · Poland

Syn2bio Spolka Akcyjna (S2B) news

Syn2bio Spolka Akcyjna is a public biotech or pharmaceutical company listed on GPW under the ticker S2B, recorded under Poland. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest Syn2bio Spolka Akcyjna news

We have not published a story on Syn2bio Spolka Akcyjna yet. When there is news, it will appear here.

Questions about Syn2bio Spolka Akcyjna

What is the ticker symbol of Syn2bio Spolka Akcyjna?

Syn2bio Spolka Akcyjna trades under the ticker S2B on GPW.

Where is Syn2bio Spolka Akcyjna listed?

Syn2bio Spolka Akcyjna is listed on GPW.

Which country or territory is Syn2bio Spolka Akcyjna listed under?

Our directory records Syn2bio Spolka Akcyjna under Poland.

What does Syn2bio Spolka Akcyjna do?

Our directory classifies Syn2bio Spolka Akcyjna as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.

What is the ISIN of Syn2bio Spolka Akcyjna?

The ISIN recorded for Syn2bio Spolka Akcyjna is PLSNBIO00013.

Does aibio.space cover Syn2bio Spolka Akcyjna?

aibio.space lists Syn2bio Spolka Akcyjna among 2,820 public biotech companies and publishes its news here as stories appear.

Which companies are similar to Syn2bio Spolka Akcyjna?

Companies in our directory listed in the same country and business area as Syn2bio Spolka Akcyjna: Biogened SA, Captor Therapeutics SA, BIOTON, Celon Pharma SA, Medicofarma Biotech Spolka Akcyjna, SYNERGA.fund SA.

Investor discussion: Syn2bio Spolka Akcyjna

Members talk about Syn2bio Spolka Akcyjna (S2B). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open GPW:S2B on TradingView.

Listing details

Syn2bio Spolka Akcyjna is a public biotech or pharmaceutical company listed on GPW under the ticker S2B, recorded under Poland. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
Syn2bio Spolka Akcyjna
Ticker
S2B
Listing
GPW
Country or territory
Poland
Business scope
Pharmaceuticals: Major
ISIN
PLSNBIO00013
Last quote in directory
2026-10-22
Directory source
Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

aibio.space

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.